Publicacions en col·laboració amb investigadors/es de VU University Amsterdam (41)

2024

  1. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  2. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Blood Advances, Vol. 8, Núm. 1, pp. 194-206

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

    Molecular cancer, Vol. 22, Núm. 1, pp. 119

  5. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  6. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

  7. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

2022

  1. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study

    Intensive Care Medicine, Vol. 48, Núm. 6, pp. 690-705

  2. Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set

    Critical Care, Vol. 26, Núm. 1

  3. Correction to: Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study (Intensive Care Medicine, (2022), 48, 6, (690-705), 10.1007/s00134-022-06705-1)

    Intensive Care Medicine

  4. Correction: Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data set (Critical Care, (2022), 26, 1, (236), 10.1186/s13054-022-04108-8)

    Critical Care

  5. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322

    Annals of oncology : official journal of the European Society for Medical Oncology

  6. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

  7. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

    Journal of Crohn's and Colitis, Vol. 16, Núm. 6, pp. 940-945

  8. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  9. Schizophrenia induces abnormal frequency-dependent patterns of dynamic brain network reconfiguration during an auditory oddball task

    Journal of neural engineering, Vol. 19, Núm. 1

  10. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Journal of Clinical Oncology, Vol. 364

  11. The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis

    Schizophrenia Bulletin Open, Vol. 3, Núm. 1